glp 1 lupus At LA’s #LatestOnLupus Conference at UCLA, Dr. Daniel Wallace shared emerging insights into the use of GLP-1 receptor agonists - commonly used to treat type 2 diabetes and obesity Exciting 2025 GLP-1 Lupus study!
Description
These adverse effects were primarily noted in people with type 2 diabetes who were using the medications
95% CI [4.110.4]
GLP-1 agonists are a class of medications that mimic the effects of natural GLP-1
19 In addition, the coformulation of SNAC and semaglutide was shown to have no extended effect on stomach mucosa
Current clinical evidence suggests minimal transfer of semaglutide and tirzepatide into breast milk, yet many healthcare providers remain cautious
